ProCE Banner Activity


Diagnosis and Management of Parkinson’s Disease Dementia


Watch this on-demand webcast of a live CCO presentation on the diagnosis and management of Parkinson’s disease dementia.

Physician Assistants: maximum of 1.00 hour of AAPA Category I credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Nurses: 1.00 Nursing contact hour

Released: October 28, 2022

Expiration: October 27, 2023



Marwan Sabbagh

Marwan Sabbagh, MD, FAAN

Professor of Neurology
Alzheimer s and Memory Disorders Division
Department of Neurology
Barrow Neurological Institute
Phoenix, Arizona

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from

Acadia Pharmaceuticals, Inc.

Target Audience

This program is intended for healthcare professionals caring for patients with Parkinson’s disease dementia, including neurologists, psychiatrists, advanced practice providers (nurse practitioners and physician associates/physician assistants), nurses, and pharmacists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify pathophysiologic and diagnostic characteristics of PDD
  • Interpret diagnostic data for differential diagnosis in PDD
  • Construct an individualized treatment plan addressing complications of dementia in Parkinson’s disease


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Marwan Sabbagh, MD, FAAN

Professor of Neurology
Alzheimer s and Memory Disorders Division
Department of Neurology
Barrow Neurological Institute
Phoenix, Arizona

Marwan Sabbagh, MD, FAAN: consultant/advisor/speaker: Alzheon, Biogen, Eisai, Genentech-Roche, KeifeRx, Lilly, NeuroTherapia, Novo Nordisk, Signant Health, Synaptogenix, T3D; ownership interest (stocks/stock options): Athira, Cortexyme/Quince Therapeutics, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, Seq BioMarque, TransDermix, uMethod Health, Versanum; royalties or patent beneficiary: Humanix.

Staff Disclosure


Raquel Gaerlan,

Director, Scientific Services

Raquel Gaerlan has no relevant financial relationships to disclose.

Gabrielle Giacona,

Associate Scientific Director

Gabrielle Giacona: individual publicly traded stocks/stock options: AstraZeneca, Moderna, Teva.

Jessie Gibson, PHD, RN, AGPCNP-BC

Jessie Gibson, PhD, RN, AGPCNP-BC: advisor/consultant/speaker: Teva.

Amber Lemons, PharmD, BCPP

Director, Educational Strategy

Amber Lemons, PharmD, BCPP, has no relevant financial relationships to disclose.

Leslie Matson, MPA, PA-C

Leslie Matson, MPA, PA-C, has no relevant financial relationships to disclose.

Lisa Phipps, PharmD, PhD

Director, Science and Strategy, Neuroscience

Lisa Phipps, PharmD, PhD, has no relevant financial relationships to disclose.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-271-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 27, 2023. PAs should only claim commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 28, 2022, through October 27, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65.00% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.



The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Parkinson’s disease dementia and its complications.